Φορτώνει......
The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular and renal outcomes in patients with type 2 diabetes, including those with diabetic kidney disease. However, the US Food and Drug Administration and European Medicines Agency warnings about potential adverse effects, such as ur...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Kidney J |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Oxford University Press
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7025347/ https://ncbi.nlm.nih.gov/pubmed/32082549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz170 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|